All In Biotech

Drug Trial Radar · NCT07600736

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

61

Planned (sponsor's estimate)

Start

May 18, 2026

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Actio Biosciences, Inc.Industry
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Conditions

  • KCNT1-Related Epilepsy

Interventions

  • ABS-1230Drug

    Daily

  • PlaceboDrug

    Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
  2. Part 2: Efficacy of ABS-1230Time frame: Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
  3. Part 3: Safety and tolerability of ABS-1230 (incidence and severity of adverse events)Time frame: Measured from Day 1 of Part 3 to End of Study or Early Termination (up to 1 year)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Northeast Regional Epilepsy Group

    Hackensack, New Jersey · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.